PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma
about
PHLPP is a negative regulator of RAF1, which reduces colorectal cancer cell motility and prevents tumor progression in miceDiverse mechanisms of AKT pathway activation in human malignancyPtdIns(4,5)P2-mediated cell signaling: emerging principles and PTEN as a paradigm for regulatory mechanismTurning off AKT: PHLPP as a drug targetSubcellular targeting and dynamic regulation of PTEN: implications for neuronal cells and neurological disordersThe PDZ Protein Na+/H+ Exchanger Regulatory Factor-1 (NHERF1) Regulates Planar Cell Polarity and Motile Cilia OrganizationStructural Insights into Neutrophilic Migration Revealed by the Crystal Structure of the Chemokine Receptor CXCR2 in Complex with the First PDZ Domain of NHERF1Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and PH domain and leucine-rich repeat phosphatase cross-talk (PHLPP) in cancer cells and in transforming growth factor β-activated stem cellsSuppression of survival signalling pathways by the phosphatase PHLPPThe EBNA3 family of Epstein-Barr virus nuclear proteins associates with the USP46/USP12 deubiquitination complexes to regulate lymphoblastoid cell line growthNHERF1/EBP50 is an organizer of polarity structures and a diagnostic marker in ependymomaRecent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical developmentHistone deacetylase inhibition destabilizes the multi-potent state of uncommitted adipose-derived mesenchymal stromal cellsChemoresistance is associated with Beclin-1 and PTEN expression in epithelial ovarian cancers.MicroRNA-3127 promotes cell proliferation and tumorigenicity in hepatocellular carcinoma by disrupting of PI3K/AKT negative regulationPleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP): a new player in cell signaling.High PHLPP expression is associated with better prognosis in patients with resected lung adenocarcinomaEmerging insights into the molecular and cellular basis of glioblastoma.NHERF1 acts as a molecular switch to program metastatic behavior and organotropism via its PDZ domains.PTEN inhibits macrophage polarization from M1 to M2 through CCL2 and VEGF-A reduction and NHERF-1 synergism.Akt Pathway Activation by Human T-cell Leukemia Virus Type 1 Tax Oncoprotein.NHERF1/EBP50 controls lactation by establishing basal membrane polarity complexes with prolactin receptor.Lower expression of PH domain leucine-rich repeat protein phosphatase 1 (PHLPP1) association with poor prognosis of gastric cancerTargeting of NHERF1 through RNA interference inhibits the proliferation and migration of metastatic prostate cancer cellsDiacylglycerol kinase δ modulates Akt phosphorylation through pleckstrin homology domain leucine-rich repeat protein phosphatase 2 (PHLPP2)Deletion of Na+/H+ exchanger regulatory factor 2 represses colon cancer progress by suppression of Stat3 and CD24.PHLPP negatively regulates cell motility through inhibition of Akt activity and integrin expression in pancreatic cancer cells.FANCI is a negative regulator of Akt activation.Ras-activated RSK1 phosphorylates EBP50 to regulate its nuclear localization and promote cell proliferation.In MMTV-Her-2/neu transgenic mammary tumors the absence of caveolin-1-/- alters PTEN and NHERF1 but not β-catenin expression.Histone deacetylase inhibition promotes osteoblast maturation by altering the histone H4 epigenome and reduces Akt phosphorylation.NHERF1/EBP50 Suppresses Wnt-β-Catenin Pathway-Driven Intestinal Neoplasia.NHERF2 is crucial in ERM phosphorylation in pulmonary endothelial cells.Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T cells.Tax-interacting protein 1 coordinates the spatiotemporal activation of Rho GTPases and regulates the infiltrative growth of human glioblastoma.Fragile X mental retardation protein promotes astrocytoma proliferation via the MEK/ERK signaling pathway.NHERF1 regulates the progression of colorectal cancer through the interplay with VEGFR2 pathwayMicroRNA-27a contributes to the malignant behavior of gastric cancer cells by directly targeting PH domain and leucine-rich repeat protein phosphatase 2.PHLPP2 suppresses the NF-κB pathway by inactivating IKKβ kinase.Signaling mechanisms regulating myelination in the central nervous system.
P2860
Q24337364-34082790-733C-401B-87E4-D47E9398D8CAQ26851604-E1226D00-2BC2-4A41-8B86-50955E56F50FQ27002565-7EA5DD8E-7E44-4B13-BA56-3E1091DFC6A3Q27014094-998A343B-5DF8-4A34-8C27-926437447303Q27022790-80F3131F-B7DA-4F0B-AE87-14D939439BE8Q27314709-C74E8890-84B3-4CF9-A0F4-1292BA652984Q27680153-8989D8F0-C685-4881-A545-0E32E5DD482EQ28384799-2DC820D7-242B-4A80-95DF-F97B09F40B58Q28388451-6872DF96-1B18-4B6B-B744-D3F31DC97127Q28546003-D7E84E89-1544-4F4D-B631-73AA3F57E4CEQ30625458-C86079E3-4070-4A8E-8EF2-E29AFB1BD0B7Q33776641-93E88A21-F35B-4709-A4C0-20B7178DCE1EQ34475885-7E64B5C1-8993-47B0-A04F-C4A90F7F4F8AQ35167494-0DB35D84-0FCF-419A-93AE-537BCD97761AQ35742539-A448064C-138C-49A3-AC3F-37DD6757CE79Q35763264-A9AD1540-061A-46ED-8459-EF45593B8A76Q35805551-8D204DFE-48BC-494B-83F1-F87F054F1A83Q35914897-89F9C45E-62C0-435B-9C3D-7E52945FA063Q35998570-A038C639-1AB7-43A5-91D4-67BC77C1E730Q36211287-052B5CBB-A901-4B8C-B131-CDD3F3D8BB7CQ36283583-08501BB1-C6BD-437B-A037-7C9A1A6BB937Q36288731-2E7D07FB-9BF8-43B2-BF64-B975C5D754EFQ36492753-EFDF3B8D-DF1C-4C7C-BC4F-68B8B08DACA2Q36524074-DDCDDB84-AC41-4BD9-844E-0CD5B53B1E54Q36543648-FD076645-3F72-47CF-9F6C-2A8570B1D3A5Q36811339-47CF35B8-04AF-4394-AD6D-04721C176F83Q36946628-9FCB08B5-D155-469D-826F-E666E1BE2A22Q36957010-D120E140-92C2-4E18-8CCB-45C14883684EQ36962945-4AA0FFF7-B4DF-4C30-8912-BEB27C4861B7Q37099496-A803D2C8-EF4A-44C5-953D-999B34CAA500Q37213816-3FC8E4C3-2515-43BA-8C34-A4773FAB40CCQ37246058-251FB407-D7A4-4143-8245-E182FDA3AB00Q37430345-4A888605-8CCA-4D29-A4EC-9B277B4EE96BQ37626146-878C88E2-2391-44F2-B30B-68888096BB46Q37662248-46C6E757-265D-46B4-83B1-E517BE098EB2Q37688952-8B62BB04-7FA9-4A60-B0AB-F2F248CBF299Q37702605-046137B8-9063-4BDA-B44D-0241391A0E5EQ37715728-83E0A5AD-BBB9-4E40-90A5-1E2C88005A6EQ37718412-F5C18DDF-0922-44E5-A9A0-0831E7524BBCQ38096247-27F21B16-23E7-475A-8A9E-99377E65DDB4
P2860
PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma
description
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2012
@ast
im März 2012 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2012/03/08)
@sk
vědecký článek publikovaný v roce 2012
@cs
wetenschappelijk artikel (gepubliceerd op 2012/03/08)
@nl
наукова стаття, опублікована в березні 2012
@uk
مقالة علمية (نشرت في 8-3-2012)
@ar
name
PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma
@ast
PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma
@en
PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma
@nl
type
label
PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma
@ast
PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma
@en
PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma
@nl
prefLabel
PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma
@ast
PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma
@en
PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma
@nl
P2093
P2860
P3181
P356
P1433
P1476
PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma
@en
P2093
F. C. Morales
J. R. Molina
K. D. Aldape
M.-M. Georgescu
N. K. Agarwal
Y. Hayashi
P2860
P2888
P304
P3181
P356
10.1038/ONC.2011.324
P407
P577
2012-03-08T00:00:00Z
P5875
P6179
1010830139